Alembic Pharmaceuticals' share price fell over 5 percent intraday to Rs 757 after the company reported a weak set of numbers for the quarter ended September 2021. The company's consolidated profit declined 49 percent year on year (YoY) at Rs 169 crore in the September quarter (Q2FY22), due to lower revenue. The pharmaceutical company had posted a profit of Rs 333 crore in the year-ago quarter. The revenue was down 11.3% at Rs 1,292.32 crore versus Rs 1,457.10 crore, YoY. The US revenue declined 40 percent to Rs 348 crore on a YoY basis. However, India's business grew 23 percent to Rs 509 crore over the previous year's quarter. Earnings before interest, tax, depreciation, and amortization (EBITDA) were down 42 percent at Rs 257.2 crore versus Rs 443.5 crore and the margin was down at 19.9% versus 30.4%, YoY. The management believes the current US sales figures ($47 million per quarter) are the new base, and these are expected to improve hereafter, led by new launches.
Read more